BrainStorm Cell Therapeutics Updates On NurOwn Stem Cell Therapy For ALS

CMC FDA Questions Resolved, PIIIb Rollout Begins, $4M Raised, Commercialization Team In Place; Signed CRO And Lined Up Commercial Manufacturer; Despite ~5% Value Range Reduction Due To Dilution, Investment Hypothesis Remains >10x Return; Exploring Non-Dilutive Grant Funds